New insights into the pathophysiology of inflammatory bowel disease: microbiota, epigenetics and common signalling pathways.

New insights into the pathophysiology of inflammatory bowel disease: microbiota, epigenetics and common signalling pathways. Swiss Med Wkly. 2018 Mar 22;148:w14599 Authors: Rogler G, Luc B, Scharl M Abstract The exact pathophysiology of inflammatory bowel disease (IBD) is still unknown. However, over the years important insights allowed the development of novel therapeutic approaches that are at the threshold of introduction into clinical practice, or at least in clinical trials. After being first described by Burrill B. Crohn, Crohn's disease, one of the two major forms of IBD, was perceived as an infectious disease. When the concept of autoimmune diseases was formulated, Crohn's disease and ulcerative colitis were thought to be members of this disease group. T cells certainly contribute to the chronification of the intestinal inflammation and targeting T cell migration has been introduced some years ago as a successful therapeutic approach in IBD. Despite the development of successful therapy based on this pathophysiological concept, IBD is no longer seen as a typical autoimmune disease. After the millennium, genome wide association studies on genetic variants and risk factors in these polygenetic diseases have told us a lot about pathogenetic pathways. However, genetic susceptibility explains only up to one third of the cases. Environmental factors also must play a role. Those environmental factors may "transfer" their disease-pro...
Source: Swiss Medical Weekly - Category: General Medicine Authors: Tags: Swiss Med Wkly Source Type: research